Keyword: Neon Therapeutics
Neon Therapeutics plans to use its IPO cash to push its lead candidate, a personalized neoantigen cancer vaccine, through phase 1.
Jan Lundberg, Ph.D., will retire next May as Dan Skovronsky, M.D., Ph.D., will be promoted to replace him.
Neon has signed a new R&D pact with gene-editing biotech CRISPR Therapeutics.
Efforts to develop effective, personalized cancer vaccines have been largely unsuccessful to date, but studies suggest the tide could be turning.
BIO elected Alnylam CEO Maraganore as new chair, Neon tapped ex-Merrimack CFO Al-Wakeel, Biogen hired ex-Shire exec Gregory to lead human resources.
Immuno-oncology startup Neon Therapeutics has teamed up with Vedantra, a vaccine delivery specialist, to try to add punch to its neoantigen vaccine pipeline.
The main reason for Novartis earning our attention is the executive and scientific talent hemorrhage in 2016, including execs David Epstein, Usman “Oz” Azam, Alessandro Riva and Hugh O'Dowd.
Welcome to our new annual feature that aims to name and shame those biopharmas and medical device companies that made an attempt at being ripe but turned out to be rotten.
Neon Therapeutics has started the year with a cash injection that will allow it to move ahead with all three of its development programs in parallel.